Summary

The research use recombinant protein market is expected to reach USD 1.55 billion in 2031 from USD 1.11 billion in 2026, registering a CAGR of 7.0% during the forecast period. The market is primarily driven by the growing pipeline of recombinant therapeutics, rising preclinical research in advanced therapies, and increasing use of proteins in tumor microenvironment studies. Cytokines, chemokines, growth factors, antigens, receptors, ligands, and enzymes are widely used across drug discovery, immunology, oncology, stem cell research, disease modeling, and cell-based assay development. The shift toward human-expressed recombinant proteins is further improving biological relevance in complex research models. In addition, ready-to-use liquid formulations and bioengineered heat-stable protein variants present opportunities for automated, high-throughput, and continuous cell culture workflows. However, market growth is constrained by lot-to-lot variability, inconsistencies in off-the-shelf proteins, and the high cost of mammalian-expressed products. Emerging non-protein alternatives and increasing supply chain complexity also remain key challenges for manufacturers and research laboratories. Human species segment to register highest CAGR during forecast period By species, the human segment is projected to exhibit the highest CAGR in the research use recombinant protein market due to the increasing use of human-derived proteins in drug discovery, translational research, disease modeling, and advanced cell-based assays. Human cytokines, growth factors, chemokines, receptors, ligands, antigens, and enzymes are widely used across oncology, immunology, neuroscience, infectious disease, and stem cell research. Growing adoption of human cell lines, organoids, and physiologically relevant experimental models is increasing demand for high-purity, biologically active, and application-specific human recombinant proteins. Cytokines & chemokines segment to hold largest market share in 2026 By product, the cytokines & chemokines segment is estimated to account for the largest share of the research use recombinant protein market, driven by their extensive use in immunology, oncology, inflammation research, stem cell studies, and drug discovery. These proteins are essential for regulating immune-cell activation, proliferation, differentiation, and migration across cell-based assays and disease models. Growing demand for interleukins, interferons, colony-stimulating factors, and chemotactic proteins in organoid development, tumor microenvironment studies, biomarker research, and translational applications continues to strengthen the position of this segment. US to register highest CAGR during forecast period In the US, the research use recombinant protein market is expected to register the highest CAGR, driven by the strong presence of leading life science companies, an advanced biomedical research infrastructure, and a high adoption rate of recombinant proteins in drug discovery and preclinical research. Expanding pipelines of recombinant therapeutics, rising research in cell and gene therapies, immuno-oncology, stem cell biology, and tumor microenvironment studies are key factors driving market growth. Human-expressed cytokines, growth factors, chemokines, antigens, receptors, and enzymes are increasingly used across pharmaceutical companies, biotechnology firms, CROs, and academic research institutes, further supporting demand. The primary interviews conducted for this report can be categorized as follows: • By Respondent: Supply Side – 70% and Demand Side– 30% • By Designation: Managers – 45%, CXOs and Directors – 30%, and Executives – 25% • By Region: North America – 40%, Europe – 25%, Asia Pacific – 25%, Latin America – 5%, Middle East & Africa – 5% Thermo Fisher Scientific Inc. (US), Bio-Techne (US), Merck KGaA (Germany), Danaher Corporation (US), Revvity (US), BPS Bioscience, Inc. (US), Bio-Rad Laboratories, Inc. (US), Sartorius AG (Germany), Sino Biological, Inc. (China), GenScript (China), Proteintech Group, Inc. (US), Miltenyi Biotec (Germany), Enzo Biochem Inc. (US), Abnova Corporation (Taiwan), STEMCELL Technologies (Canada), RayBiotech, Inc. (US), ProSpec-Tany TechnoGene Ltd. (Israel), ProteoGenix (France), Aviva Systems Biology Corporation (US), Elabscience (US), Qkine Ltd. (UK), Abbexa (UK), Bon Opus Biosciences, LLC (US), Novoprotein Scientific Inc. (China), and OriGene Technologies, Inc. (US) are some of the key companies offering research use recombinant proteins. Research Coverage This research report categorizes the research use recombinant protein market by product (cytokines & chemokines, growth factors, recombinant antigens, receptors & ligands, enzymes, ECM & adhesion proteins, and other recombinant proteins), product formulation (lyophilized and liquid recombinant proteins), species (human, mouse, rat, non-human primate, and other species), host cell (mammalian cells, insect cells, bacterial cells, yeast & fungi cells, and other host cells), application (cell culture & differentiation, drug discovery, cancer research, stem cell research, infectious disease & vaccine research, and other applications), end user (pharmaceutical & biotechnology companies, academic & research institutes, contract research organizations, and other end users), and region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa). The report’s scope encompasses detailed information about the primary factors, including drivers, restraints, challenges, and opportunities, that influence the growth of the research use recombinant protein market. A comprehensive analysis of key industry players has been performed to provide insights into their business overview, product portfolio, key strategies, new product launches, acquisitions, and recent developments related to the research use recombinant protein market. This report also includes a competitive analysis of emerging startups in the research use recombinant protein industry ecosystem. Key Benefits of Buying the Report The report will assist market leaders and new entrants by providing revenue estimates for the overall market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to position their businesses effectively and develop suitable go-to-market strategies. This report will enable stakeholders to grasp the market's pulse and offer information on key market drivers, restraints, opportunities, and challenges. The report provides insights into the following pointers: • Analysis of key drivers (growing pipeline for recombinant therapeutic proteins, rising preclinical research activities in advanced therapies, shift towards human-expressed recombinant proteins for research use applications, increase in demand for research use recombinant proteins in tumor microenvironment studies), restraints (high lot-to-lot variability and inconsistency in off-the-shelf recombinant proteins for research use applications, high costs associated with premium recombinant proteins expressed in mammalian cells), opportunities (emergence of ready-to-use liquid formulations for integration into automated high-throughput workflows, development of bio-engineered, heat-stable protein variants for continuous cell lines & cell culture), and challenges (advent of non-protein mimics and alternative modalities, rising supply chain complexities) influencing the market growth • Product Development/Innovation: Detailed insights into newly launched products and innovations in the research use recombinant protein market • Market Development: Comprehensive information about lucrative markets and analysis of the market across varied regions • Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the research use recombinant protein market • Competitive Assessment: In-depth assessment of market shares, growth strategies, and products of leading players, such as Thermo Fisher Scientific Inc. (US), Bio-Techne (US), Merck KGaA (Germany), Danaher Corporation (US), Revvity (US), BPS Bioscience, Inc. (US), Bio-Rad Laboratories, Inc. (US), and Sartorius AG (Germany), among others, for the research use recombinant protein market

ページTOPに戻る

Table of Contents

1 INTRODUCTION 37
1.1 STUDY OBJECTIVES 37
1.2 MARKET DEFINITION 37
1.3 STUDY SCOPE 37
1.3.1 MARKET SEGMENTATION AND REGIONS COVERED 38
1.3.2 INCLUSIONS & EXCLUSIONS 39
1.3.3 YEARS CONSIDERED 39
1.3.4 CURRENCY CONSIDERED 40
1.4 STAKEHOLDERS 40
2 EXECUTIVE SUMMARY 41
2.1 MARKET HIGHLIGHTS AND KEY INSIGHTS 41
2.2 KEY MARKET PARTICIPANTS: MAPPING OF STRATEGIC DEVELOPMENTS 43
2.3 DISRUPTIVE TRENDS IN RUO RECOMBINANT PROTEIN MARKET 44
2.4 HIGH-GROWTH SEGMENTS 45
2.5 REGIONAL SNAPSHOT: MARKET SIZE, GROWTH RATE, AND FORECAST 46
3 PREMIUM INSIGHTS 47
3.1 RUO RECOMBINANT PROTEIN MARKET OVERVIEW 47
3.2 NORTH AMERICA: RUO RECOMBINANT PROTEIN MARKET, BY PRODUCT FORMULATION 48
3.3 RUO RECOMBINANT PROTEIN MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 49
3.4 RUO RECOMBINANT PROTEIN MARKET SHARE, BY END USER, 2026 VS 2031 (%) 50
4 MARKET OVERVIEW 51
4.1 INTRODUCTION 51
4.2 MARKET DYNAMICS 52
4.2.1 DRIVERS 53
4.2.1.1 Growing pipeline for recombinant therapeutic proteins 53
4.2.1.2 Rising preclinical research in advanced therapies (cell & gene therapies) 54
4.2.1.3 Shift toward human-expressed recombinant proteins for RUO applications 55
4.2.1.4 Rising demand for RUO recombinant proteins in tumor microenvironment studies 55
4.2.2 RESTRAINTS 56
4.2.2.1 High lot-to-lot variability and inconsistency in off-the-shelf recombinant proteins for research-use applications 56
4.2.2.2 High costs associated with premium recombinant proteins expressed in mammalian cells 57
 
4.2.3 OPPORTUNITIES 57
4.2.3.1 Emergence of ready-to-use liquid formulations for integration into automated high-throughput workflows 57
4.2.3.2 Development of bioengineered, heat-stable protein variants for continuous cell lines & cell culture 58
4.2.4 CHALLENGES 58
4.2.4.1 Advent of non-protein mimics and alternative modalities 58
4.2.4.2 Rising supply chain complexities 59
4.3 UNMET NEEDS AND WHITE SPACES 59
4.4 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES 60
4.5 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS 61
5 INDUSTRY TRENDS 62
5.1 PORTER’S FIVE FORCES ANALYSIS 62
5.1.1 INTENSITY OF COMPETITIVE RIVALRY 63
5.1.2 BARGAINING POWER OF SUPPLIERS 63
5.1.3 BARGAINING POWER OF BUYERS 64
5.1.4 THREAT OF SUBSTITUTES 64
5.1.5 THREAT OF NEW ENTRANTS 64
5.2 MACROECONOMIC OUTLOOK 64
5.2.1 INTRODUCTION 64
5.2.2 GDP TRENDS AND FORECASTS 65
5.2.3 TRENDS IN GLOBAL HEALTHCARE INDUSTRY 65
5.2.4 TRENDS IN GLOBAL BIOTECH INDUSTRY 66
5.3 VALUE CHAIN ANALYSIS 66
5.4 ECOSYSTEM ANALYSIS 68
5.4.1 ROLE OF PLAYERS IN ECOSYSTEM 69
5.5 PRICING ANALYSIS 70
5.5.1 AVERAGE SELLING PRICE TREND, BY KEY PLAYER, 2023–2025 71
5.5.2 AVERAGE SELLING PRICE TREND, BY REGION, 2023–2025 72
5.6 TRADE ANALYSIS 74
5.6.1 IMPORT SCENARIO (HS CODE 3822.00) 74
5.6.2 EXPORT SCENARIO (HS CODE 3822.00) 75
5.7 KEY CONFERENCES & EVENTS, 2026–2027 76
5.8 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 77
5.9 INVESTMENT & FUNDING SCENARIO 77
5.10 CASE STUDY ANALYSIS 79
5.10.1 RECOMBINANT LIGAND SCREENING MAPS INFLAMED INTESTINAL ORGANOID RESPONSES 79
5.10.2 RECOMBINANT OSTEOGLYCIN SUPPORTS ALVEOLAR ORGANOID RESEARCH 79
5.10.3 RECOMBINANT ANTIGENS IMPROVE H. PYLORI ASSAY DEVELOPMENT 79
 
5.11 IMPACT OF US TARIFFS—RUO RECOMBINANT PROTEIN MARKET 79
5.11.1 INTRODUCTION 79
5.11.2 KEY TARIFF RATES 80
5.11.3 PRICE IMPACT ANALYSIS 81
5.11.4 IMPACT ON COUNTRIES/REGIONS 82
5.11.4.1 US 82
5.11.4.2 Europe 83
5.11.4.3 Asia Pacific 83
5.11.5 IMPACT ON END-USE INDUSTRIES 84
5.11.5.1 Pharmaceutical & biotechnology companies 84
5.11.5.2 Academic & research institutes 84
5.11.5.3 CROs 85
6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS 86
6.1 INTRODUCTION 86
6.2 KEY TECHNOLOGIES 86
6.2.1 CODON OPTIMIZATION 86
6.2.2 CRISPR/CAS9 ENGINEERING 87
6.2.3 TRANSIENT GENE EXPRESSION (TGE) 87
6.3 COMPLEMENTARY TECHNOLOGIES 87
6.3.1 AFFINITY CHROMATOGRAPHY 87
6.3.2 TANGENTIAL FLOW FILTRATION (TFF) AND ULTRAFILTRATION 88
6.4 ADJACENT TECHNOLOGIES 88
6.4.1 GENE EDITING 88
6.4.2 SPATIAL MULTI-OMICS 89
6.5 TECHNOLOGY ROADMAP 89
6.6 PATENT ANALYSIS 90
6.6.1 METHODOLOGY 90
6.6.2 NUMBER OF PATENTS FILED, BY DOCUMENT TYPE 90
6.6.3 LIST OF KEY PATENTS 92
6.7 FUTURE APPLICATIONS 93
6.8 IMPACT OF AI/GEN AI ON RUO RECOMBINANT PROTEIN MARKET 93
6.8.1 TOP USE CASES AND MARKET POTENTIAL 94
6.8.2 BEST PRACTICES IN AI-ENABLED RECOMBINANT PROTEIN DISCOVERY, DESIGN, AND WORKFLOWS 95
6.8.3 CASE STUDIES OF AI IMPLEMENTATION IN RUO RECOMBINANT
PROTEIN MARKET 95
6.8.4 INTERCONNECTED ADJACENT ECOSYSTEMS AND IMPACT
ON MARKET PLAYERS 96
6.8.5 CLIENTS’ READINESS TO ADOPT AI-INTEGRATED RECOMBINANT
PROTEIN SOLUTIONS 96
7 REGULATORY LANDSCAPE AND SUSTAINABILITY INITIATIVES 98
7.1 REGIONAL REGULATIONS AND COMPLIANCE 98
7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 98
7.1.2 INDUSTRY STANDARDS 102
7.1.2.1 North America 102
7.1.2.2 Europe 102
7.1.2.3 Asia Pacific 103
7.1.2.4 Rest of the world 104
7.2 SUSTAINABILITY INITIATIVES 104
7.3 IMPACT OF REGULATORY POLICIES ON SUSTAINABILITY INITIATIVES 105
7.4 CERTIFICATIONS, LABELING, AND ECO-STANDARDS 105
8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR 109
8.1 DECISION-MAKING PROCESS 109
8.2 BUYER STAKEHOLDERS AND BUYING EVALUATION CRITERIA 109
8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS 109
8.2.2 KEY BUYING CRITERIA, BY END USER 110
8.3 ADOPTION BARRIERS & INTERNAL CHALLENGES 112
8.4 UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES 112
9 RESEARCH USE ONLY (RUO) RECOMBINANT PROTEIN MARKET, BY PRODUCT 114
9.1 INTRODUCTION 115
9.2 CYTOKINES & CHEMOKINES 115
9.2.1 EXPANDING IMMUNE-CELL RESEARCH TO BOOST MARKET GROWTH 115
9.3 GROWTH FACTORS 119
9.3.1 EXPANDING STEM CELL, ORGANOID, AND TISSUE-MODEL RESEARCH TO FUEL SEGMENT GROWTH 119
9.4 RECOMBINANT ANTIGENS 122
9.4.1 INFECTIOUS-DISEASE AND ANTIBODY RESEARCH TO DRIVE MARKET 122
9.5 RECEPTORS & LIGANDS 126
9.5.1 INCREASING USE OF RECOMBINANT RECEPTORS AND LIGANDS TO DRIVE MARKET 126
9.6 ENZYMES 129
9.6.1 EXPANDING MOLECULAR RESEARCH TO DRIVE MARKET 129
9.7 ECM & ADHESION PROTEINS 133
9.7.1 STEM CELL AND 3D CULTURE RESEARCH TO DRIVE MARKET 133
9.8 OTHER RECOMBINANT PROTEINS 136
 
10 RESEARCH USE ONLY (RUO) RECOMBINANT PROTEIN MARKET,
BY PRODUCT FORMULATION 140
10.1 INTRODUCTION 141
10.2 LYOPHILIZED RECOMBINANT PROTEINS 141
10.2.1 IMPROVED STABILITY, SIMPLIFIED DISTRIBUTION, AND CONSISTENT RESEARCH PERFORMANCE TO DRIVE MARKET GROWTH 141
10.3 LIQUID RECOMBINANT PROTEINS 145
10.3.1 CONVENIENCE, PRECISE DOSING, AND AUTOMATION-COMPATIBLE WORKFLOWS TO SUPPORT GROWTH 145
11 RESEARCH USE ONLY (RUO) RECOMBINANT PROTEIN MARKET, BY SPECIES 149
11.1 INTRODUCTION 150
11.2 HUMAN 150
11.2.1 EXPANDING HUMAN-RELEVANT MODELS AND TRANSLATIONAL RESEARCH TO BOOST MARKET GROWTH 150
11.3 MOUSE 154
11.3.1 EXPANDING MURINE DISEASE MODELS AND SPECIES-MATCHED CELL CULTURE WORKFLOWS TO FUEL SEGMENT 154
11.4 RAT 157
11.4.1 EXPANDING RAT-BASED PRECLINICAL MODELS AND SPECIES-MATCHED RESEARCH WORKFLOWS TO DRIVE MARKET 157
11.5 NON-HUMAN PRIMATE 161
11.5.1 EXPANDING TRANSLATIONAL VALIDATION AND ADVANCED BIOLOGIC DEVELOPMENT TO DRIVE MARKET 161
11.6 OTHER SPECIES 164
12 RESEARCH USE ONLY (RUO) RECOMBINANT PROTEIN MARKET,
BY HOST CELL 168
12.1 INTRODUCTION 169
12.2 MAMMALIAN CELLS 169
12.2.1 GROWING BIOLOGICS RESEARCH TO BOOST MARKET GROWTH 169
12.3 BACTERIAL CELLS 173
12.3.1 COST-EFFECTIVE AND RAPID PROTEIN PRODUCTION TO DRIVE MARKET 173
12.4 INSECT CELLS 176
12.4.1 GROWING RESEARCH ON COMPLEX PROTEINS AND VIRAL TARGETS
TO FUEL GROWTH 176
12.5 YEAST & FUNGI CELLS 180
12.5.1 SCALABLE AND COST-EFFICIENT PROTEIN PRODUCTION TO DRIVE MARKET 180
12.6 OTHER HOST CELLS 183
 
13 RESEARCH USE ONLY (RUO) RECOMBINANT PROTEIN MARKET,
BY APPLICATION 187
13.1 INTRODUCTION 188
13.2 CELL CULTURE & DIFFERENTIATION 188
13.2.1 GROWTH IN STEM-CELL, ORGANOID, AND ADVANCED CELL-CULTURE RESEARCH TO BOOST MARKET GROWTH 188
13.3 DRUG DISCOVERY 192
13.3.1 EXPANDING BIOLOGICS RESEARCH AND TARGET SCREENING
TO FUEL SEGMENT 192
13.4 CANCER RESEARCH 195
13.4.1 EXPANDING IMMUNO-ONCOLOGY AND PRECISION CANCER RESEARCH TO DRIVE MARKET 195
13.5 STEM CELL RESEARCH 199
13.5.1 GROWTH IN STEM CELL, ORGANOID, AND REGENERATIVE MEDICINE RESEARCH TO DRIVE MARKET 199
13.6 INFECTIOUS DISEASE & VACCINE RESEARCH 202
13.6.1 EMERGING PATHOGENS AND EVOLVING VIRAL STRAINS TO DRIVE MARKET 202
13.7 OTHER APPLICATIONS 206
14 RESEARCH USE ONLY (RUO) RECOMBINANT PROTEIN MARKET, BY END USER 210
14.1 INTRODUCTION 211
14.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 212
14.2.1 EXPANDING THERAPEUTIC PIPELINES, ADVANCED CELL MODELS, AND ENGINEERED PROTEINS TO BOOST MARKET GROWTH 212
14.3 ACADEMIC & RESEARCH INSTITUTES 215
14.3.1 PUBLIC RESEARCH FUNDING AND ADVANCED HUMAN DISEASE MODELS TO FUEL SEGMENT 215
14.4 CONTRACT RESEARCH ORGANIZATIONS 219
14.4.1 EXPANDING R&D OUTSOURCING TO DRIVE MARKET 219
14.5 OTHER END USERS 222
15 RESEARCH USE ONLY (RUO) RECOMBINANT PROTEIN MARKET, BY REGION 226
15.1 INTRODUCTION 227
15.2 NORTH AMERICA 228
15.2.1 US 232
15.2.1.1 Research funding, advanced cellular models, and engineered protein innovation to drive market 232
15.2.2 CANADA 236
15.2.2.1 Government funding and regenerative medicine leadership to propel market 236
15.3 EUROPE 239
15.3.1 GERMANY 243
15.3.1.1 Biotechnology clusters, translational research, and supplier expansion to aid market growth 243
15.3.2 UK 247
15.3.2.1 Advanced cellular models and animal-origin-free protein innovation to drive market 247
15.3.3 FRANCE 250
15.3.3.1 Immuno-oncology research to drive market 250
15.3.4 ITALY 254
15.3.4.1 Advanced research infrastructure and biotechnology collaboration to drive market 254
15.3.5 SPAIN 257
15.3.5.1 AI-enabled protein design and collaborative biomedical infrastructure to aid growth 257
15.3.6 REST OF EUROPE 261
15.4 ASIA PACIFIC 264
15.4.1 CHINA 269
15.4.1.1 AI-enabled protein engineering and localized reagent production to boost market 269
15.4.2 JAPAN 272
15.4.2.1 Regenerative medicine expertise and development of application-specific recombinant proteins to drive market growth 272
15.4.3 INDIA 276
15.4.3.1 Research outsourcing capabilities and expanding scientific infrastructure to propel market 276
15.4.4 AUSTRALIA 279
15.4.4.1 Integrated protein-research infrastructure and translational science to fuel market 279
15.4.5 SOUTH KOREA 283
15.4.5.1 Synthetic biology, organoid-based screening, and AI-enabled discovery to support market growth 283
15.4.6 REST OF ASIA PACIFIC 286
15.5 LATIN AMERICA 290
15.5.1 BRAZIL 294
15.5.1.1 Infectious-disease research, shared protein-production infrastructure, and vaccine innovation to drive market 294
15.5.2 MEXICO 297
15.5.2.1 Expanding use of high-quality recombinant proteins in global translational workflows to support market 297
15.5.3 REST OF LATIN AMERICA 301
15.6 MIDDLE EAST 304
15.6.1 GCC COUNTRIES 307
15.6.1.1 Saudi Arabia 311
15.6.1.1.1 Biotechnology policy and advanced-therapy infrastructure to boost market 311
15.6.1.2 UAE 315
15.6.1.2.1 AI-enabled human-relevant models and integrated biotechnology infrastructure to aid market growth 315
 
15.6.1.3 Rest of GCC Countries 318
15.6.2 REST OF MIDDLE EAST 322
15.7 AFRICA 325
15.7.1 INFECTIOUS-DISEASE RESEARCH AND LOCALIZED RECOMBINANT PROTEIN PRODUCTION TO PROPEL MARKET 325
16 COMPETITIVE LANDSCAPE 329
16.1 INTRODUCTION 329
16.2 KEY PLAYER STRATEGIES/RIGHT TO WIN, JANUARY 2023–JUNE 2026 329
16.3 REVENUE ANALYSIS 331
16.4 MARKET SHARE ANALYSIS, 2025 332
16.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025 334
16.5.1 STARS 335
16.5.2 EMERGING LEADERS 335
16.5.3 PERVASIVE PLAYERS 335
16.5.4 PARTICIPANTS 335
16.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025 337
16.5.5.1 Company footprint 337
16.5.5.2 Region footprint 338
16.5.5.3 Product footprint 339
16.5.5.4 Application footprint 340
16.5.5.5 Species footprint 341
16.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025 342
16.6.1 PROGRESSIVE COMPANIES 342
16.6.2 RESPONSIVE COMPANIES 342
16.6.3 DYNAMIC COMPANIES 342
16.6.4 STARTING BLOCKS 342
16.6.5 COMPETITIVE BENCHMARKING 344
16.6.5.1 Detailed list of key startups/SMEs 344
16.6.5.2 Competitive benchmarking of key startups/SMEs 345
16.7 COMPANY VALUATION AND FINANCIAL METRICS 346
16.7.1 COMPANY VALUATION 346
16.7.2 FINANCIAL METRICS 346
16.8 BRAND COMPARISON 347
16.9 COMPETITIVE SCENARIO 348
16.9.1 PRODUCT LAUNCHES 348
16.9.2 DEALS 349
16.9.3 EXPANSIONS 350
 
17 COMPANY PROFILES 351
17.1 KEY PLAYERS 351
17.1.1 THERMO FISHER SCIENTIFIC INC. 351
17.1.1.1 Business overview 351
17.1.1.2 Products offered 352
17.1.1.3 Recent developments 355
17.1.1.3.1 Product launches 355
17.1.1.3.2 Deals 355
17.1.1.4 MnM view 356
17.1.1.4.1 Key strengths 356
17.1.1.4.2 Strategic choices 356
17.1.1.4.3 Weaknesses and competitive threats 356
17.1.2 MERCK KGAA 357
17.1.2.1 Business overview 357
17.1.2.2 Products offered 359
17.1.2.3 Recent developments 363
17.1.2.3.1 Deals 363
17.1.2.3.2 Expansions 363
17.1.2.4 MnM view 363
17.1.2.4.1 Key strengths 363
17.1.2.4.2 Strategic choices 364
17.1.2.4.3 Weaknesses and competitive threats 364
17.1.3 BIO-TECHNE 365
17.1.3.1 Business overview 365
17.1.3.2 Products offered 366
17.1.3.3 Recent developments 370
17.1.3.3.1 Product launches 370
17.1.3.3.2 Deals 371
17.1.3.4 MnM view 371
17.1.3.4.1 Key strengths 371
17.1.3.4.2 Strategic choices 371
17.1.3.4.3 Weaknesses and competitive threats 371
17.1.4 DANAHER CORPORATION 372
17.1.4.1 Business overview 372
17.1.4.2 Products offered 373
17.1.4.3 Recent developments 377
17.1.4.3.1 Product launches 377
17.1.4.3.2 Deals 377
17.1.4.4 MnM view 378
17.1.4.4.1 Key strengths 378
17.1.4.4.2 Strategic choices 378
17.1.4.4.3 Weaknesses and competitive threats 378
17.1.5 REVVITY 379
17.1.5.1 Business overview 379
17.1.5.2 Products offered 380
17.1.5.3 Recent developments 385
17.1.5.3.1 Expansions 385
17.1.5.4 MnM view 385
17.1.5.4.1 Key strengths 385
17.1.5.4.2 Strategic choices 385
17.1.5.4.3 Weaknesses and competitive threats 385
17.1.6 BIO-RAD LABORATORIES, INC. 386
17.1.6.1 Business overview 386
17.1.6.2 Products offered 387
17.1.6.3 Recent developments 390
17.1.6.3.1 Product launches 390
17.1.7 BPS BIOSCIENCE, INC. 391
17.1.7.1 Business overview 391
17.1.7.2 Products offered 391
17.1.8 SARTORIUS AG 395
17.1.8.1 Business overview 395
17.1.8.2 Products offered 396
17.1.9 SINO BIOLOGICAL, INC. 400
17.1.9.1 Business overview 400
17.1.9.2 Products offered 400
17.1.10 GENSCRIPT 405
17.1.10.1 Business overview 405
17.1.10.2 Products offered 406
17.1.11 PROTEINTECH GROUP, INC. 411
17.1.11.1 Business overview 411
17.1.11.2 Products offered 411
17.1.11.3 Recent developments 413
17.1.11.3.1 Deals 413
17.1.12 MILTENYI BIOTEC 414
17.1.12.1 Business overview 414
17.1.12.2 Products offered 414
17.1.12.3 Recent developments 417
17.1.12.3.1 Product launches 417
17.1.13 ENZO BIOCHEM, INC. 418
17.1.13.1 Business overview 418
17.1.13.2 Products offered 418
17.1.13.3 Recent developments 421
17.1.13.3.1 Deals 421
 
17.1.14 ABNOVA CORPORATION 422
17.1.14.1 Business overview 422
17.1.14.2 Products offered 423
17.2 OTHER PLAYERS 427
17.2.1 STEMCELL TECHNOLOGIES 427
17.2.2 RAYBIOTECH, INC. 428
17.2.3 PROSPEC-TANY TECHNOGENE LTD. 429
17.2.4 PROTEOGENIX 430
17.2.5 AVIVA SYSTEMS BIOLOGY CORPORATION 432
17.2.6 ELABSCIENCE 433
17.2.7 QKINE LTD. 435
17.2.8 ABBEXA 436
17.2.9 BON OPUS BIOSCIENCES, LLC 437
17.2.10 NOVOPROTEIN SCIENTIFIC INC. 439
17.2.11 ORIGENE TECHNOLOGIES, INC. 440
18 RESEARCH METHODOLOGY 442
18.1 RESEARCH DATA 442
18.1.1 SECONDARY DATA 443
18.1.1.1 Key data from secondary sources 443
18.1.2 PRIMARY DATA 444
18.1.2.1 Key data from primary sources 444
18.1.2.2 Key primary participants 444
18.1.2.3 Breakdown of primary interviews 445
18.1.2.4 Key industry insights 446
18.2 MARKET SIZE ESTIMATION 446
18.2.1 GLOBAL RUO RECOMBINANT PROTEIN MARKET ESTIMATION, 2025 447
18.2.2 SEGMENTAL MARKET SIZE ESTIMATION 449
18.3 MARKET GROWTH RATE PROJECTIONS 451
18.4 DATA TRIANGULATION 452
18.5 FACTOR ANALYSIS 453
18.6 RESEARCH ASSUMPTIONS 453
18.7 RESEARCH LIMITATIONS AND RISK ASSESSMENT 454
19 APPENDIX 456
19.1 DISCUSSION GUIDE 456
19.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 460
19.3 CUSTOMIZATION OPTIONS 462
19.4 RELATED REPORTS 462
19.5 AUTHOR DETAILS 463

ページTOPに戻る

List of Tables/Graphs

TABLE 1 RUO RECOMBINANT PROTEIN MARKET: INCLUSIONS AND EXCLUSIONS 39
TABLE 2 RUO RECOMBINANT PROTEIN MARKET: IMPACT ANALYSIS OF MARKET DYNAMICS 52
TABLE 3 KEY PIPELINE PRODUCTS IN STEM CELL THERAPY (AS OF 2025) 54
TABLE 4 RUO RECOMBINANT PROTEIN MARKET: PORTER’S FIVE FORCES 62
TABLE 5 RUO RECOMBINANT PROTEIN MARKET: ROLE OF PLAYERS IN ECOSYSTEM 69
TABLE 6 AVERAGE SELLING PRICE TREND OF RESEARCH-USE RECOMBINANT PROTEINS,
BY KEY PLAYER, 2023–2025 (USD) 71
TABLE 7 AVERAGE SELLING PRICE TREND OF RUO RECOMBINANT PROTEINS,
BY REGION, 2023–2025 (USD) 72
TABLE 8 IMPORT DATA FOR HS CODE 3822.00-COMPLIANT PRODUCTS,
BY COUNTRY, 2021–2025 (USD THOUSAND) 74
TABLE 9 EXPORT DATA FOR HS CODE 3822.00-COMPLIANT PRODUCTS,
BY COUNTRY, 2021–2025 (USD THOUSAND) 75
TABLE 10 RUO RECOMBINANT PROTEIN MARKET: LIST OF KEY CONFERENCES &
EVENTS, JANUARY 2026–JUNE 2027 76
TABLE 11 RECIPROCAL TARIFF RATES ADJUSTED BY US 80
TABLE 12 CRITICAL COMPONENTS LIKELY EXPOSED TO TARIFF CHANGES 82
TABLE 13 NUMBER OF PATENTS FILED, BY DOCUMENT TYPE, 2015–2025 90
TABLE 14 LIST OF KEY PATENTS IN RUO RECOMBINANT PROTEIN MARKET, 2023–2025 92
TABLE 15 CASE STUDIES OF AI IMPLEMENTATION IN RUO RECOMBINANT PROTEIN MARKET 95
TABLE 16 CLIENTS’ READINESS TO ADOPT AI-INTEGRATED RECOMBINANT PROTEIN SOLUTIONS IN RUO RECOMBINANT PROTEIN MARKET 97
TABLE 17 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 98
TABLE 18 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 99
TABLE 19 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 99
TABLE 20 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT
AGENCIES, AND OTHER ORGANIZATIONS 101
TABLE 21 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS, BY PRODUCT 110
TABLE 22 KEY BUYING CRITERIA, BY END USER 111
TABLE 23 RUO RECOMBINANT PROTEIN MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 115
TABLE 24 RUO RECOMBINANT PROTEIN MARKET FOR CYTOKINES & CHEMOKINES,
BY REGION, 2024–2031 (USD MILLION) 116
TABLE 25 NORTH AMERICA: RUO RECOMBINANT PROTEIN MARKET FOR CYTOKINES & CHEMOKINES, BY COUNTRY, 2024–2031 (USD MILLION) 116
TABLE 26 EUROPE: RUO RECOMBINANT PROTEIN MARKET FOR CYTOKINES & CHEMOKINES, BY COUNTRY, 2024–2031 (USD MILLION) 117
TABLE 27 ASIA PACIFIC: RUO RECOMBINANT PROTEIN MARKET FOR CYTOKINES & CHEMOKINES, BY COUNTRY, 2024–2031 (USD MILLION) 117
TABLE 28 LATIN AMERICA: RUO RECOMBINANT PROTEIN MARKET FOR CYTOKINES & CHEMOKINES, BY COUNTRY, 2024–2031 (USD MILLION) 118
TABLE 29 MIDDLE EAST: RUO RECOMBINANT PROTEIN MARKET FOR CYTOKINES & CHEMOKINES, BY REGION, 2024–2031 (USD MILLION) 118
TABLE 30 GCC COUNTRIES: RUO RECOMBINANT PROTEIN MARKET FOR CYTOKINES & CHEMOKINES, BY COUNTRY, 2024–2031 (USD MILLION) 118
TABLE 31 RUO RECOMBINANT PROTEIN MARKET FOR GROWTH FACTORS, BY REGION, 2024–2031 (USD MILLION) 119
TABLE 32 NORTH AMERICA: RUO RECOMBINANT PROTEIN MARKET FOR GROWTH FACTORS, BY COUNTRY, 2024–2031 (USD MILLION) 120
TABLE 33 EUROPE: RUO RECOMBINANT PROTEIN MARKET FOR GROWTH FACTORS,
BY COUNTRY, 2024–2031 (USD MILLION) 120
TABLE 34 ASIA PACIFIC: RUO RECOMBINANT PROTEIN MARKET FOR GROWTH FACTORS,
BY COUNTRY, 2024–2031 (USD MILLION) 121
TABLE 35 LATIN AMERICA: RUO RECOMBINANT PROTEIN MARKET FOR GROWTH FACTORS, BY COUNTRY, 2024–2031 (USD MILLION) 121
TABLE 36 MIDDLE EAST: RUO RECOMBINANT PROTEIN MARKET FOR GROWTH FACTORS,
BY REGION, 2024–2031 (USD MILLION) 122
TABLE 37 GCC COUNTRIES: RUO RECOMBINANT PROTEIN MARKET FOR GROWTH FACTORS, BY COUNTRY, 2024–2031 (USD MILLION) 122
TABLE 38 RUO RECOMBINANT PROTEIN MARKET FOR RECOMBINANT ANTIGENS, BY REGION, 2024–2031 (USD MILLION) 123
TABLE 39 NORTH AMERICA: RUO RECOMBINANT PROTEIN MARKET FOR RECOMBINANT ANTIGENS, BY COUNTRY, 2024–2031 (USD MILLION) 123
TABLE 40 EUROPE: RUO RECOMBINANT PROTEIN MARKET FOR RECOMBINANT ANTIGENS, BY COUNTRY, 2024–2031 (USD MILLION) 124
TABLE 41 ASIA PACIFIC: RUO RECOMBINANT PROTEIN MARKET FOR RECOMBINANT ANTIGENS, BY COUNTRY, 2024–2031 (USD MILLION) 124
TABLE 42 LATIN AMERICA: RUO RECOMBINANT PROTEIN MARKET FOR RECOMBINANT ANTIGENS, BY COUNTRY, 2024–2031 (USD MILLION) 125
TABLE 43 MIDDLE EAST: RUO RECOMBINANT PROTEIN MARKET FOR RECOMBINANT ANTIGENS, BY REGION, 2024–2031 (USD MILLION) 125
TABLE 44 GCC COUNTRIES: RUO RECOMBINANT PROTEIN MARKET FOR RECOMBINANT ANTIGENS, BY COUNTRY, 2024–2031 (USD MILLION) 125
TABLE 45 RUO RECOMBINANT PROTEIN MARKET FOR RECEPTORS & LIGANDS, BY REGION, 2024–2031 (USD MILLION) 126
TABLE 46 NORTH AMERICA: RUO RECOMBINANT PROTEIN MARKET FOR RECEPTORS & LIGANDS, BY COUNTRY, 2024–2031 (USD MILLION) 127
TABLE 47 EUROPE: RUO RECOMBINANT PROTEIN MARKET FOR RECEPTORS & LIGANDS,
BY COUNTRY, 2024–2031 (USD MILLION) 127
TABLE 48 ASIA PACIFIC: RUO RECOMBINANT PROTEIN MARKET FOR RECEPTORS & LIGANDS, BY COUNTRY, 2024–2031 (USD MILLION) 128
TABLE 49 LATIN AMERICA: RUO RECOMBINANT PROTEIN MARKET FOR RECEPTORS & LIGANDS, BY COUNTRY, 2024–2031 (USD MILLION) 128
TABLE 50 MIDDLE EAST: RUO RECOMBINANT PROTEIN MARKET FOR RECEPTORS & LIGANDS, BY REGION, 2024–2031 (USD MILLION) 129
TABLE 51 GCC COUNTRIES: RUO RECOMBINANT PROTEIN MARKET FOR RECEPTORS & LIGANDS, BY COUNTRY, 2024–2031 (USD MILLION) 129
TABLE 52 RUO RECOMBINANT PROTEIN MARKET FOR ENZYMES, BY REGION,
2024–2031 (USD MILLION) 130
TABLE 53 NORTH AMERICA: RUO RECOMBINANT PROTEIN MARKET FOR ENZYMES,
BY COUNTRY, 2024–2031 (USD MILLION) 130
TABLE 54 EUROPE: RUO RECOMBINANT PROTEIN MARKET FOR ENZYMES, BY COUNTRY, 2024–2031 (USD MILLION) 131
TABLE 55 ASIA PACIFIC: RUO RECOMBINANT PROTEIN MARKET FOR ENZYMES, BY COUNTRY, 2024–2031 (USD MILLION) 131
TABLE 56 LATIN AMERICA: RUO RECOMBINANT PROTEIN MARKET FOR ENZYMES,
BY COUNTRY, 2024–2031 (USD MILLION) 132
TABLE 57 MIDDLE EAST: RUO RECOMBINANT PROTEIN MARKET FOR ENZYMES,
BY REGION, 2024–2031 (USD MILLION) 132
TABLE 58 GCC COUNTRIES: RUO RECOMBINANT PROTEIN MARKET FOR ENZYMES,
BY COUNTRY, 2024–2031 (USD MILLION) 132
TABLE 59 RUO RECOMBINANT PROTEIN MARKET FOR ECM & ADHESION PROTEINS,
BY REGION, 2024–2031 (USD MILLION) 133
TABLE 60 NORTH AMERICA: RUO RECOMBINANT PROTEIN MARKET FOR ECM & ADHESION PROTEINS, BY COUNTRY, 2024–2031 (USD MILLION) 134
TABLE 61 EUROPE: RUO RECOMBINANT PROTEIN MARKET FOR ECM & ADHESION PROTEINS, BY COUNTRY, 2024–2031 (USD MILLION) 134
TABLE 62 ASIA PACIFIC: RUO RECOMBINANT PROTEIN MARKET FOR ECM & ADHESION PROTEINS, BY COUNTRY, 2024–2031 (USD MILLION) 135
TABLE 63 LATIN AMERICA: RUO RECOMBINANT PROTEIN MARKET FOR ECM & ADHESION PROTEINS, BY COUNTRY, 2024–2031 (USD MILLION) 135
TABLE 64 MIDDLE EAST: RUO RECOMBINANT PROTEIN MARKET FOR ECM & ADHESION PROTEINS, BY REGION, 2024–2031 (USD MILLION) 136
TABLE 65 GCC COUNTRIES: RUO RECOMBINANT PROTEIN MARKET FOR ECM & ADHESION PROTEINS, BY COUNTRY, 2024–2031 (USD MILLION) 136
TABLE 66 RUO RECOMBINANT PROTEIN MARKET FOR OTHER RECOMBINANT PROTEINS,
BY REGION, 2024–2031 (USD MILLION) 137
TABLE 67 NORTH AMERICA: RUO RECOMBINANT PROTEIN MARKET FOR OTHER RECOMBINANT PROTEINS, BY COUNTRY, 2024–2031 (USD MILLION) 137
TABLE 68 EUROPE: RUO RECOMBINANT PROTEIN MARKET FOR OTHER RECOMBINANT PROTEINS, BY COUNTRY, 2024–2031 (USD MILLION) 138
TABLE 69 ASIA PACIFIC: RUO RECOMBINANT PROTEIN MARKET FOR OTHER RECOMBINANT PROTEINS, BY COUNTRY, 2024–2031 (USD MILLION) 138
TABLE 70 LATIN AMERICA: RUO RECOMBINANT PROTEIN MARKET FOR OTHER RECOMBINANT PROTEINS, BY COUNTRY, 2024–2031 (USD MILLION) 139
TABLE 71 MIDDLE EAST: RUO RECOMBINANT PROTEIN MARKET FOR OTHER RECOMBINANT PROTEINS, BY REGION, 2024–2031 (USD MILLION) 139
TABLE 72 GCC COUNTRIES: RUO RECOMBINANT PROTEIN MARKET FOR OTHER RECOMBINANT PROTEINS, BY COUNTRY, 2024–2031 (USD MILLION) 139
TABLE 73 RUO RECOMBINANT PROTEIN MARKET, BY PRODUCT FORMULATION,
2024–2031 (USD MILLION) 141
TABLE 74 RUO RECOMBINANT PROTEIN MARKET FOR LYOPHILIZED RECOMBINANT PROTEINS, BY REGION, 2024–2031 (USD MILLION) 142
TABLE 75 NORTH AMERICA: RUO RECOMBINANT PROTEIN MARKET FOR LYOPHILIZED RECOMBINANT PROTEINS, BY COUNTRY, 2024–2031 (USD MILLION) 142
TABLE 76 EUROPE: RUO RECOMBINANT PROTEIN MARKET FOR LYOPHILIZED RECOMBINANT PROTEINS, BY COUNTRY, 2024–2031 (USD MILLION) 143
TABLE 77 ASIA PACIFIC: RUO RECOMBINANT PROTEIN MARKET FOR LYOPHILIZED RECOMBINANT PROTEINS, BY COUNTRY, 2024–2031 (USD MILLION) 143
TABLE 78 LATIN AMERICA: RUO RECOMBINANT PROTEIN MARKET FOR LYOPHILIZED RECOMBINANT PROTEINS, BY COUNTRY, 2024–2031 (USD MILLION) 144
TABLE 79 MIDDLE EAST: RUO RECOMBINANT PROTEIN MARKET FOR LYOPHILIZED RECOMBINANT PROTEINS, BY REGION, 2024–2031 (USD MILLION) 144
TABLE 80 GCC COUNTRIES: RUO RECOMBINANT PROTEIN MARKET FOR LYOPHILIZED RECOMBINANT PROTEINS, BY COUNTRY, 2024–2031 (USD MILLION) 144
TABLE 81 RUO RECOMBINANT PROTEIN MARKET FOR LIQUID RECOMBINANT PROTEINS,
BY REGION, 2024–2031 (USD MILLION) 145
TABLE 82 NORTH AMERICA: RUO RECOMBINANT PROTEIN MARKET FOR LIQUID RECOMBINANT PROTEINS, BY COUNTRY, 2024–2031 (USD MILLION) 146
TABLE 83 EUROPE: RUO RECOMBINANT PROTEIN MARKET FOR LIQUID RECOMBINANT PROTEINS, BY COUNTRY, 2024–2031 (USD MILLION) 146
TABLE 84 ASIA PACIFIC: RUO RECOMBINANT PROTEIN MARKET FOR LIQUID RECOMBINANT PROTEINS, BY COUNTRY, 2024–2031 (USD MILLION) 147
TABLE 85 LATIN AMERICA: RUO RECOMBINANT PROTEIN MARKET FOR LIQUID RECOMBINANT PROTEINS, BY COUNTRY, 2024–2031 (USD MILLION) 147
TABLE 86 MIDDLE EAST: RUO RECOMBINANT PROTEIN MARKET FOR LIQUID RECOMBINANT PROTEINS, BY REGION, 2024–2031 (USD MILLION) 148
TABLE 87 GCC COUNTRIES: RUO RECOMBINANT PROTEIN MARKET FOR LIQUID RECOMBINANT PROTEINS, BY COUNTRY, 2024–2031 (USD MILLION) 148
TABLE 88 RUO RECOMBINANT PROTEIN MARKET, BY SPECIES, 2024–2031 (USD MILLION) 150
TABLE 89 HUMAN RUO RECOMBINANT PROTEINS MARKET, BY REGION,
2024–2031 (USD MILLION) 151
TABLE 90 NORTH AMERICA: HUMAN RUO RECOMBINANT PROTEINS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 151
TABLE 91 EUROPE: HUMAN RUO RECOMBINANT PROTEINS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 152
TABLE 92 ASIA PACIFIC: HUMAN RUO RECOMBINANT PROTEINS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 152
TABLE 93 LATIN AMERICA: HUMAN RUO RECOMBINANT PROTEINS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 153
TABLE 94 MIDDLE EAST: HUMAN RUO RECOMBINANT PROTEINS MARKET, BY REGION, 2024–2031 (USD MILLION) 153
TABLE 95 GCC COUNTRIES: HUMAN RUO RECOMBINANT PROTEINS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 153
TABLE 96 MOUSE RUO RECOMBINANT PROTEINS MARKET, BY REGION,
2024–2031 (USD MILLION) 154
TABLE 97 NORTH AMERICA: MOUSE RUO RECOMBINANT PROTEINS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 155
TABLE 98 EUROPE: MOUSE RUO RECOMBINANT PROTEINS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 155
TABLE 99 ASIA PACIFIC: MOUSE RUO RECOMBINANT PROTEINS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 156
TABLE 100 LATIN AMERICA: MOUSE RUO RECOMBINANT PROTEINS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 156
TABLE 101 MIDDLE EAST: MOUSE RUO RECOMBINANT PROTEINS MARKET, BY REGION, 2024–2031 (USD MILLION) 157
TABLE 102 GCC COUNTRIES: MOUSE RUO RECOMBINANT PROTEINS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 157
TABLE 103 RAT RUO RECOMBINANT PROTEINS MARKET, BY REGION,
2024–2031 (USD MILLION) 158
TABLE 104 NORTH AMERICA: RAT RUO RECOMBINANT PROTEINS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 158
TABLE 105 EUROPE: RAT RUO RECOMBINANT PROTEINS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 159
TABLE 106 ASIA PACIFIC: RAT RUO RECOMBINANT PROTEINS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 159
TABLE 107 LATIN AMERICA: RAT RUO RECOMBINANT PROTEINS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 160
TABLE 108 MIDDLE EAST: RAT RUO RECOMBINANT PROTEINS MARKET, BY REGION,
2024–2031 (USD MILLION) 160
TABLE 109 GCC COUNTRIES: RAT RUO RECOMBINANT PROTEINS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 160
TABLE 110 NON-HUMAN PRIMATE RUO RECOMBINANT PROTEINS MARKET, BY REGION, 2024–2031 (USD MILLION) 161
TABLE 111 NORTH AMERICA: NON-HUMAN PRIMATE RUO RECOMBINANT PROTEINS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 162
TABLE 112 EUROPE: NON-HUMAN PRIMATE RUO RECOMBINANT PROTEINS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 162
TABLE 113 ASIA PACIFIC: NON-HUMAN PRIMATE RUO RECOMBINANT PROTEINS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 163
TABLE 114 LATIN AMERICA: NON-HUMAN PRIMATE RUO RECOMBINANT PROTEINS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 163
TABLE 115 MIDDLE EAST: NON-HUMAN PRIMATE RUO RECOMBINANT PROTEINS MARKET,
BY REGION, 2024–2031 (USD MILLION) 164
TABLE 116 GCC COUNTRIES: NON-HUMAN PRIMATE RUO RECOMBINANT PROTEINS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 164
TABLE 117 RUO RECOMBINANT PROTEIN MARKET FOR OTHER SPECIES, BY REGION,
2024–2031 (USD MILLION) 165
TABLE 118 NORTH AMERICA: RUO RECOMBINANT PROTEIN MARKET FOR OTHER SPECIES,
BY COUNTRY, 2024–2031 (USD MILLION) 165
TABLE 119 EUROPE: RUO RECOMBINANT PROTEIN MARKET FOR OTHER SPECIES,
BY COUNTRY, 2024–2031 (USD MILLION) 166
TABLE 120 ASIA PACIFIC: RUO RECOMBINANT PROTEIN MARKET FOR OTHER SPECIES,
BY COUNTRY, 2024–2031 (USD MILLION) 166
TABLE 121 LATIN AMERICA: RUO RECOMBINANT PROTEIN MARKET FOR OTHER SPECIES,
BY COUNTRY, 2024–2031 (USD MILLION) 167
TABLE 122 MIDDLE EAST: RUO RECOMBINANT PROTEIN MARKET FOR OTHER SPECIES,
BY REGION, 2024–2031 (USD MILLION) 167
TABLE 123 GCC COUNTRIES: RUO RECOMBINANT PROTEIN MARKET FOR OTHER SPECIES,
BY COUNTRY, 2024–2031 (USD MILLION) 167
TABLE 124 RUO RECOMBINANT PROTEIN MARKET, BY HOST CELL,
2024–2031 (USD MILLION) 169
TABLE 125 RUO RECOMBINANT PROTEIN MARKET FOR MAMMALIAN CELLS, BY REGION, 2024–2031 (USD MILLION) 170
TABLE 126 NORTH AMERICA: RUO RECOMBINANT PROTEIN MARKET FOR MAMMALIAN CELLS, BY COUNTRY, 2024–2031 (USD MILLION) 170
TABLE 127 EUROPE: RUO RECOMBINANT PROTEIN MARKET FOR MAMMALIAN CELLS,
BY COUNTRY, 2024–2031 (USD MILLION) 171
TABLE 128 ASIA PACIFIC: RUO RECOMBINANT PROTEIN MARKET FOR MAMMALIAN CELLS,
BY COUNTRY, 2024–2031 (USD MILLION) 171
TABLE 129 LATIN AMERICA: RUO RECOMBINANT PROTEIN MARKET FOR MAMMALIAN CELLS, BY COUNTRY, 2024–2031 (USD MILLION) 172
TABLE 130 MIDDLE EAST: RUO RECOMBINANT PROTEIN MARKET FOR MAMMALIAN CELLS,
BY REGION, 2024–2031 (USD MILLION) 172
TABLE 131 GCC COUNTRIES: RUO RECOMBINANT PROTEIN MARKET FOR MAMMALIAN CELLS, BY COUNTRY, 2024–2031 (USD MILLION) 172
TABLE 132 RUO RECOMBINANT PROTEIN MARKET FOR BACTERIAL CELLS, BY REGION,
2024–2031 (USD MILLION) 173
TABLE 133 NORTH AMERICA: RUO RECOMBINANT PROTEIN MARKET FOR BACTERIAL CELLS, BY COUNTRY, 2024–2031 (USD MILLION) 174
TABLE 134 EUROPE: RUO RECOMBINANT PROTEIN MARKET FOR BACTERIAL CELLS,
BY COUNTRY, 2024–2031 (USD MILLION) 174
TABLE 135 ASIA PACIFIC: RUO RECOMBINANT PROTEIN MARKET FOR BACTERIAL CELLS,
BY COUNTRY, 2024–2031 (USD MILLION) 175
TABLE 136 LATIN AMERICA: RUO RECOMBINANT PROTEIN MARKET FOR BACTERIAL CELLS,
BY COUNTRY, 2024–2031 (USD MILLION) 175
TABLE 137 MIDDLE EAST: RUO RECOMBINANT PROTEIN MARKET FOR BACTERIAL CELLS,
BY REGION, 2024–2031 (USD MILLION) 176
TABLE 138 GCC COUNTRIES: RUO RECOMBINANT PROTEIN MARKET FOR BACTERIAL CELLS, BY COUNTRY, 2024–2031 (USD MILLION) 176
TABLE 139 RUO RECOMBINANT PROTEIN MARKET FOR INSECT CELLS, BY REGION,
2024–2031 (USD MILLION) 177
TABLE 140 NORTH AMERICA: RUO RECOMBINANT PROTEIN MARKET FOR INSECT CELLS,
BY COUNTRY, 2024–2031 (USD MILLION) 177
TABLE 141 EUROPE: RUO RECOMBINANT PROTEIN MARKET FOR INSECT CELLS, BY COUNTRY, 2024–2031 (USD MILLION) 178
TABLE 142 ASIA PACIFIC: RUO RECOMBINANT PROTEIN MARKET FOR INSECT CELLS,
BY COUNTRY, 2024–2031 (USD MILLION) 178
TABLE 143 LATIN AMERICA: RUO RECOMBINANT PROTEIN MARKET FOR INSECT CELLS,
BY COUNTRY, 2024–2031 (USD MILLION) 179
TABLE 144 MIDDLE EAST: RUO RECOMBINANT PROTEIN MARKET FOR INSECT CELLS,
BY REGION, 2024–2031 (USD MILLION) 179
TABLE 145 GCC COUNTRIES: RUO RECOMBINANT PROTEIN MARKET FOR INSECT CELLS,
BY COUNTRY, 2024–2031 (USD MILLION) 179
TABLE 146 RUO RECOMBINANT PROTEIN MARKET FOR YEAST & FUNGI CELLS, BY REGION, 2024–2031 (USD MILLION) 180
TABLE 147 NORTH AMERICA: RUO RECOMBINANT PROTEIN MARKET FOR YEAST & FUNGI CELLS, BY COUNTRY, 2024–2031 (USD MILLION) 181
TABLE 148 EUROPE: RUO RECOMBINANT PROTEIN MARKET FOR YEAST & FUNGI CELLS,
BY COUNTRY, 2024–2031 (USD MILLION) 181
TABLE 149 ASIA PACIFIC: RUO RECOMBINANT PROTEIN MARKET FOR YEAST & FUNGI CELLS, BY COUNTRY, 2024–2031 (USD MILLION) 182
TABLE 150 LATIN AMERICA: RUO RECOMBINANT PROTEIN MARKET FOR YEAST & FUNGI CELLS, BY COUNTRY, 2024–2031 (USD MILLION) 182
TABLE 151 MIDDLE EAST: RUO RECOMBINANT PROTEIN MARKET FOR YEAST & FUNGI CELLS, BY REGION, 2024–2031 (USD MILLION) 183
TABLE 152 GCC COUNTRIES: RUO RECOMBINANT PROTEIN MARKET FOR YEAST & FUNGI CELLS, BY COUNTRY, 2024–2031 (USD MILLION) 183
TABLE 153 RUO RECOMBINANT PROTEIN MARKET FOR OTHER HOST CELLS, BY REGION, 2024–2031 (USD MILLION) 184
TABLE 154 NORTH AMERICA: RUO RECOMBINANT PROTEIN MARKET FOR OTHER HOST CELLS, BY COUNTRY, 2024–2031 (USD MILLION) 184
TABLE 155 EUROPE: RUO RECOMBINANT PROTEIN MARKET FOR OTHER HOST CELLS,
BY COUNTRY, 2024–2031 (USD MILLION) 185
TABLE 156 ASIA PACIFIC: RUO RECOMBINANT PROTEIN MARKET FOR OTHER HOST CELLS,
BY COUNTRY, 2024–2031 (USD MILLION) 185
TABLE 157 LATIN AMERICA: RUO RECOMBINANT PROTEIN MARKET FOR OTHER HOST CELLS, BY COUNTRY, 2024–2031 (USD MILLION) 186
TABLE 158 MIDDLE EAST: RUO RECOMBINANT PROTEIN MARKET FOR OTHER HOST CELLS,
BY REGION, 2024–2031 (USD MILLION) 186
TABLE 159 GCC COUNTRIES: RUO RECOMBINANT PROTEIN MARKET FOR OTHER HOST CELLS, BY COUNTRY, 2024–2031 (USD MILLION) 186
TABLE 160 RUO RECOMBINANT PROTEIN MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 188
TABLE 161 RUO RECOMBINANT PROTEIN MARKET FOR CELL CULTURE & DIFFERENTIATION, BY REGION, 2024–2031 (USD MILLION) 189
TABLE 162 NORTH AMERICA: RUO RECOMBINANT PROTEIN MARKET FOR CELL CULTURE & DIFFERENTIATION, BY COUNTRY, 2024–2031 (USD MILLION) 189
TABLE 163 EUROPE: RUO RECOMBINANT PROTEIN MARKET FOR CELL CULTURE & DIFFERENTIATION, BY COUNTRY, 2024–2031 (USD MILLION) 190
TABLE 164 ASIA PACIFIC: RUO RECOMBINANT PROTEIN MARKET FOR CELL CULTURE & DIFFERENTIATION, BY COUNTRY, 2024–2031 (USD MILLION) 190
TABLE 165 LATIN AMERICA: RUO RECOMBINANT PROTEIN MARKET FOR CELL CULTURE & DIFFERENTIATION, BY COUNTRY, 2024–2031 (USD MILLION) 191
TABLE 166 MIDDLE EAST: RUO RECOMBINANT PROTEIN MARKET FOR CELL CULTURE & DIFFERENTIATION, BY REGION, 2024–2031 (USD MILLION) 191
TABLE 167 GCC COUNTRIES: RUO RECOMBINANT PROTEIN MARKET FOR CELL CULTURE & DIFFERENTIATION, BY COUNTRY, 2024–2031 (USD MILLION) 191
TABLE 168 RUO RECOMBINANT PROTEIN MARKET FOR DRUG DISCOVERY, BY REGION,
2024–2031 (USD MILLION) 192
TABLE 169 NORTH AMERICA: RUO RECOMBINANT PROTEIN MARKET FOR DRUG DISCOVERY, BY COUNTRY, 2024–2031 (USD MILLION) 193
TABLE 170 EUROPE: RUO RECOMBINANT PROTEIN MARKET FOR DRUG DISCOVERY,
BY COUNTRY, 2024–2031 (USD MILLION) 193
TABLE 171 ASIA PACIFIC: RUO RECOMBINANT PROTEIN MARKET FOR DRUG DISCOVERY,
BY COUNTRY, 2024–2031 (USD MILLION) 194
TABLE 172 LATIN AMERICA: RUO RECOMBINANT PROTEIN MARKET FOR DRUG DISCOVERY,
BY COUNTRY, 2024–2031 (USD MILLION) 194
TABLE 173 MIDDLE EAST: RUO RECOMBINANT PROTEIN MARKET FOR DRUG DISCOVERY,
BY REGION, 2024–2031 (USD MILLION) 195
TABLE 174 GCC COUNTRIES: RUO RECOMBINANT PROTEIN MARKET FOR DRUG DISCOVERY, BY COUNTRY, 2024–2031 (USD MILLION) 195
TABLE 175 RUO RECOMBINANT PROTEIN MARKET FOR CANCER RESEARCH, BY REGION, 2024–2031 (USD MILLION) 196
TABLE 176 NORTH AMERICA: RUO RECOMBINANT PROTEIN MARKET FOR CANCER RESEARCH, BY COUNTRY, 2024–2031 (USD MILLION) 196
TABLE 177 EUROPE: RUO RECOMBINANT PROTEIN MARKET FOR CANCER RESEARCH,
BY COUNTRY, 2024–2031 (USD MILLION) 197
TABLE 178 ASIA PACIFIC: RUO RECOMBINANT PROTEIN MARKET FOR CANCER RESEARCH,
BY COUNTRY, 2024–2031 (USD MILLION) 197
TABLE 179 LATIN AMERICA: RUO RECOMBINANT PROTEIN MARKET FOR CANCER RESEARCH, BY COUNTRY, 2024–2031 (USD MILLION) 198
TABLE 180 MIDDLE EAST: RUO RECOMBINANT PROTEIN MARKET FOR CANCER RESEARCH,
BY REGION, 2024–2031 (USD MILLION) 198
TABLE 181 GCC COUNTRIES: RUO RECOMBINANT PROTEIN MARKET FOR CANCER RESEARCH, BY COUNTRY, 2024–2031 (USD MILLION) 198
TABLE 182 RUO RECOMBINANT PROTEIN MARKET FOR STEM CELL RESEARCH, BY REGION, 2024–2031 (USD MILLION) 199
TABLE 183 NORTH AMERICA: RUO RECOMBINANT PROTEIN MARKET FOR STEM CELL RESEARCH, BY COUNTRY, 2024–2031 (USD MILLION) 200
TABLE 184 EUROPE: RUO RECOMBINANT PROTEIN MARKET FOR STEM CELL RESEARCH,
BY COUNTRY, 2024–2031 (USD MILLION) 200
TABLE 185 ASIA PACIFIC: RUO RECOMBINANT PROTEIN MARKET FOR STEM CELL RESEARCH, BY COUNTRY, 2024–2031 (USD MILLION) 201
TABLE 186 LATIN AMERICA: RUO RECOMBINANT PROTEIN MARKET FOR STEM CELL RESEARCH, BY COUNTRY, 2024–2031 (USD MILLION) 201
TABLE 187 MIDDLE EAST: RUO RECOMBINANT PROTEIN MARKET FOR STEM CELL RESEARCH, BY REGION, 2024–2031 (USD MILLION) 202
TABLE 188 GCC COUNTRIES: RUO RECOMBINANT PROTEIN MARKET FOR STEM CELL RESEARCH, BY COUNTRY, 2024–2031 (USD MILLION) 202
TABLE 189 RUO RECOMBINANT PROTEIN MARKET FOR INFECTIOUS DISEASE & VACCINE RESEARCH, BY REGION, 2024–2031 (USD MILLION) 203
TABLE 190 NORTH AMERICA: RUO RECOMBINANT PROTEIN MARKET FOR INFECTIOUS DISEASE & VACCINE RESEARCH, BY COUNTRY, 2024–2031 (USD MILLION) 203
TABLE 191 EUROPE: RUO RECOMBINANT PROTEIN MARKET FOR INFECTIOUS DISEASE & VACCINE RESEARCH, BY COUNTRY, 2024–2031 (USD MILLION) 204
TABLE 192 ASIA PACIFIC: RUO RECOMBINANT PROTEIN MARKET FOR INFECTIOUS DISEASE & VACCINE RESEARCH, BY COUNTRY, 2024–2031 (USD MILLION) 204
TABLE 193 LATIN AMERICA: RUO RECOMBINANT PROTEIN MARKET FOR INFECTIOUS DISEASE & VACCINE RESEARCH, BY COUNTRY, 2024–2031 (USD MILLION) 205
TABLE 194 MIDDLE EAST: RUO RECOMBINANT PROTEIN MARKET FOR INFECTIOUS DISEASE & VACCINE RESEARCH, BY REGION, 2024–2031 (USD MILLION) 205
TABLE 195 GCC COUNTRIES: RUO RECOMBINANT PROTEIN MARKET FOR INFECTIOUS DISEASE & VACCINE RESEARCH, BY COUNTRY, 2024–2031 (USD MILLION) 205
TABLE 196 RUO RECOMBINANT PROTEIN MARKET FOR OTHER APPLICATIONS, BY REGION, 2024–2031 (USD MILLION) 206
TABLE 197 NORTH AMERICA: RUO RECOMBINANT PROTEIN MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 207
TABLE 198 EUROPE: RUO RECOMBINANT PROTEIN MARKET FOR OTHER APPLICATIONS,
BY COUNTRY, 2024–2031 (USD MILLION) 207
TABLE 199 ASIA PACIFIC: RUO RECOMBINANT PROTEIN MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 208
TABLE 200 LATIN AMERICA: RUO RECOMBINANT PROTEIN MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 208
TABLE 201 MIDDLE EAST: RUO RECOMBINANT PROTEIN MARKET FOR OTHER APPLICATIONS, BY REGION, 2024–2031 (USD MILLION) 209
TABLE 202 GCC COUNTRIES: RUO RECOMBINANT PROTEIN MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 209
TABLE 203 RUO RECOMBINANT PROTEIN MARKET, BY END USER, 2024–2031 (USD MILLION) 211
TABLE 204 RUO RECOMBINANT PROTEIN MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2024–2031 (USD MILLION) 212
TABLE 205 NORTH AMERICA: RUO RECOMBINANT PROTEIN MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION) 213
TABLE 206 EUROPE: RUO RECOMBINANT PROTEIN MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION) 213
TABLE 207 ASIA PACIFIC: RUO RECOMBINANT PROTEIN MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION) 214
TABLE 208 LATIN AMERICA: RUO RECOMBINANT PROTEIN MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION) 214
TABLE 209 MIDDLE EAST: RUO RECOMBINANT PROTEIN MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2024–2031 (USD MILLION) 215
TABLE 210 GCC COUNTRIES: RUO RECOMBINANT PROTEIN MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION) 215
TABLE 211 RUO RECOMBINANT PROTEIN MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2024–2031 (USD MILLION) 216
TABLE 212 NORTH AMERICA: RUO RECOMBINANT PROTEIN MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION) 216
TABLE 213 EUROPE: RUO RECOMBINANT PROTEIN MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION) 217
TABLE 214 ASIA PACIFIC: RUO RECOMBINANT PROTEIN MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION) 217
TABLE 215 LATIN AMERICA: RUO RECOMBINANT PROTEIN MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION) 218
TABLE 216 MIDDLE EAST: RUO RECOMBINANT PROTEIN MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2024–2031 (USD MILLION) 218
TABLE 217 GCC COUNTRIES: RUO RECOMBINANT PROTEIN MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION) 218
TABLE 218 RUO RECOMBINANT PROTEIN MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2024–2031 (USD MILLION) 219
TABLE 219 NORTH AMERICA: RUO RECOMBINANT PROTEIN MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 220
TABLE 220 EUROPE: RUO RECOMBINANT PROTEIN MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 220
TABLE 221 ASIA PACIFIC: RUO RECOMBINANT PROTEIN MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 221
TABLE 222 LATIN AMERICA: RUO RECOMBINANT PROTEIN MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 221
TABLE 223 MIDDLE EAST: RUO RECOMBINANT PROTEIN MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2024–2031 (USD MILLION) 222
TABLE 224 GCC COUNTRIES: RUO RECOMBINANT PROTEIN MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 222
TABLE 225 RUO RECOMBINANT PROTEIN MARKET FOR OTHER END USERS, BY REGION, 2024–2031 (USD MILLION) 223
TABLE 226 NORTH AMERICA: RUO RECOMBINANT PROTEIN MARKET FOR OTHER END USERS, BY COUNTRY, 2024–2031 (USD MILLION) 223
TABLE 227 EUROPE: RUO RECOMBINANT PROTEIN MARKET FOR OTHER END USERS, BY COUNTRY, 2024–2031 (USD MILLION) 224
TABLE 228 ASIA PACIFIC: RUO RECOMBINANT PROTEIN MARKET FOR OTHER END USERS,
BY COUNTRY, 2024–2031 (USD MILLION) 224
TABLE 229 LATIN AMERICA: RUO RECOMBINANT PROTEIN MARKET FOR OTHER END USERS, BY COUNTRY, 2024–2031 (USD MILLION) 225
TABLE 230 MIDDLE EAST: RUO RECOMBINANT PROTEIN MARKET FOR OTHER END USERS,
BY REGION, 2024–2031 (USD MILLION) 225
TABLE 231 GCC COUNTRIES: RUO RECOMBINANT PROTEIN MARKET FOR OTHER END USERS, BY COUNTRY, 2024–2031 (USD MILLION) 225
TABLE 232 RUO RECOMBINANT PROTEIN MARKET, BY REGION, 2024–2031 (USD MILLION) 227
TABLE 233 NORTH AMERICA: RUO RECOMBINANT PROTEIN MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 229
TABLE 234 NORTH AMERICA: RUO RECOMBINANT PROTEIN MARKET, BY PRODUCT,
2024–2031 (USD MILLION) 229
TABLE 235 NORTH AMERICA: RUO RECOMBINANT PROTEIN MARKET, BY PRODUCT FORMULATION, 2024–2031 (USD MILLION) 230
TABLE 236 NORTH AMERICA: RUO RECOMBINANT PROTEIN MARKET, BY SPECIES,
2024–2031 (USD MILLION) 230
TABLE 237 NORTH AMERICA: RUO RECOMBINANT PROTEIN MARKET, BY HOST CELL,
2024–2031 (USD MILLION) 231
TABLE 238 NORTH AMERICA: RUO RECOMBINANT PROTEIN MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 231
TABLE 239 NORTH AMERICA: RUO RECOMBINANT PROTEIN MARKET, BY END USER,
2024–2031 (USD MILLION) 232
TABLE 240 US: RUO RECOMBINANT PROTEIN MARKET, BY PRODUCT,
2024–2031 (USD MILLION) 233
TABLE 241 US: RUO RECOMBINANT PROTEIN MARKET, BY PRODUCT FORMULATION,
2024–2031 (USD MILLION) 233
TABLE 242 US: RUO RECOMBINANT PROTEIN MARKET, BY SPECIES,
2024–2031 (USD MILLION) 234
TABLE 243 US: RUO RECOMBINANT PROTEIN MARKET, BY HOST CELL,
2024–2031 (USD MILLION) 234
TABLE 244 US: RUO RECOMBINANT PROTEIN MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 235
TABLE 245 US: RUO RECOMBINANT PROTEIN MARKET, BY END USER,
2024–2031 (USD MILLION) 235
TABLE 246 CANADA: RUO RECOMBINANT PROTEIN MARKET, BY PRODUCT,
2024–2031 (USD MILLION) 236
TABLE 247 CANADA: RUO RECOMBINANT PROTEIN MARKET, BY PRODUCT FORMULATION, 2024–2031 (USD MILLION) 237
TABLE 248 CANADA: RUO RECOMBINANT PROTEIN MARKET, BY SPECIES,
2024–2031 (USD MILLION) 237
TABLE 249 CANADA: RUO RECOMBINANT PROTEIN MARKET, BY HOST CELL,
2024–2031 (USD MILLION) 238
TABLE 250 CANA
FIGURE 1 RUO RECOMBINANT PROTEIN MARKET SEGMENTATION
AND REGIONS CONSIDERED 38
FIGURE 2 RUO RECOMBINANT PROTEIN MARKET: YEARS CONSIDERED 39
FIGURE 3 MARKET SCENARIO 42
FIGURE 4 GLOBAL RUO RECOMBINANT PROTEIN MARKET, 2024–2031 42
FIGURE 5 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN RUO
RECOMBINANT PROTEIN MARKET, 2023–2026 43
FIGURE 6 DISRUPTIONS INFLUENCING GROWTH OF RUO RECOMBINANT PROTEIN MARKET 44
FIGURE 7 HIGH-GROWTH SEGMENTS IN RUO RECOMBINANT PROTEIN MARKET, 2026–2031 45
FIGURE 8 ASIA PACIFIC TO REGISTER HIGHEST CAGR IN RUO RECOMBINANT PROTEIN MARKET, IN TERMS OF VALUE, DURING FORECAST PERIOD 46
FIGURE 9 RISING ADOPTION OF CELL-BASED THERAPIES AND REGENERATIVE
MEDICINE TO DRIVE MARKET GROWTH 47
FIGURE 10 LYOPHILIZED RECOMBINANT PROTEINS ACCOUNTED FOR LARGEST MARKET SHARE IN 2025 48
FIGURE 11 ASIA PACIFIC IS LIKELY TO BE FASTEST-GROWING MARKET TILL 2031 49
FIGURE 12 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES TO DOMINATE MARKET DURING FORECAST PERIOD 50
FIGURE 13 RUO RECOMBINANT PROTEIN MARKET: DRIVERS, RESTRAINTS,
OPPORTUNITIES, AND CHALLENGES 52
FIGURE 14 RUO RECOMBINANT PROTEIN MARKET: PORTER’S FIVE FORCES ANALYSIS 63
FIGURE 15 RUO RECOMBINANT PROTEIN MARKET: VALUE CHAIN ANALYSIS 67
FIGURE 16 RUO RECOMBINANT PROTEIN MARKET: ECOSYSTEM ANALYSIS 69
FIGURE 17 AVERAGE SELLING PRICE OF RESEARCH-USE RECOMBINANT PROTEINS,
BY KEY PLAYER, 2025 (USD) 72
FIGURE 18 AVERAGE SELLING PRICE OF RESEARCH-USE RECOMBINANT PROTEINS,
BY REGION, 2025 (USD) 73
FIGURE 19 RUO RECOMBINANT PROTEIN MARKET: TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 77
FIGURE 20 INVESTMENT AND FUNDING SCENARIO, 2023–2025 (USD MILLION) 78
FIGURE 21 PATENT APPLICATIONS IN RUO RECOMBINANT PROTEIN MARKET,
JANUARY 2015–DECEMBER 2025 91
FIGURE 22 IMPACT OF AI/GEN AI ON RUO RECOMBINANT PROTEIN MARKET 94
FIGURE 23 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS, BY PRODUCT 109
FIGURE 24 KEY BUYING CRITERIA, BY END USER 110
FIGURE 25 NORTH AMERICA: RUO RECOMBINANT PROTEIN MARKET SNAPSHOT 228
FIGURE 26 ASIA PACIFIC: RUO RECOMBINANT PROTEIN MARKET SNAPSHOT 265
FIGURE 27 REVENUE ANALYSIS OF KEY PLAYERS IN RUO RECOMBINANT
PROTEIN MARKET, 2021–2025 332
FIGURE 28 RUO RECOMBINANT PROTEIN MARKET SHARE ANALYSIS, 2025 333
FIGURE 29 RUO RECOMBINANT PROTEIN MARKET: COMPANY EVALUATION MATRIX
(KEY PLAYERS), 2025 336
FIGURE 30 RUO RECOMBINANT PROTEIN MARKET: COMPANY FOOTPRINT 337
FIGURE 31 RUO RECOMBINANT PROTEIN MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2025 343
FIGURE 32 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK
BETA OF KEY VENDORS 346
FIGURE 33 EV/EBITDA OF KEY VENDORS 346
FIGURE 34 RUO RECOMBINANT PROTEIN MARKET: BRAND COMPARATIVE ANALYSIS 347
FIGURE 35 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2025) 352
FIGURE 36 MERCK KGAA: COMPANY SNAPSHOT (2025) 358
FIGURE 37 BIO-TECHNE: COMPANY SNAPSHOT (2025) 366
FIGURE 38 DANAHER CORPORATION: COMPANY SNAPSHOT (2025) 373
FIGURE 39 REVVITY: COMPANY SNAPSHOT (2025) 380
FIGURE 40 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2025) 387
FIGURE 41 SARTORIUS AG: COMPANY SNAPSHOT (2025) 396
FIGURE 42 GENSCRIPT: COMPANY SNAPSHOT (2025) 406
FIGURE 43 ABNOVA CORPORATION: COMPANY SNAPSHOT (2024) 423
FIGURE 44 RUO RECOMBINANT PROTEIN MARKET: RESEARCH DESIGN 442
FIGURE 45 RUO RECOMBINANT PROTEIN MARKET: BREAKDOWN OF PRIMARIES 445
FIGURE 46 RUO RECOMBINANT PROTEIN MARKET: INSIGHTS FROM PRIMARIES 446
FIGURE 47 GLOBAL RUO RECOMBINANT PROTEIN MARKET ESTIMATION, 2025 447
FIGURE 48 RUO RECOMBINANT PROTEIN MARKET: COMPANY REVENUE
ANALYSIS-BASED ESTIMATION (BOTTOM-UP APPROACH) (2025) 448
FIGURE 49 ILLUSTRATIVE EXAMPLE OF THERMO FISHER SCIENTIFIC INC.:
REVENUE ANALYSIS (2025) 448
FIGURE 50 SEGMENTAL MARKET SIZE ESTIMATION: TOP-DOWN APPROACH 449
FIGURE 51 RUO RECOMBINANT PROTEIN MARKET: CAGR PROJECTIONS 451
FIGURE 52 RUO RECOMBINANT PROTEIN MARKET: DATA TRIANGULATION 452